Parlux Q2
This article was originally published in The Rose Sheet
Executive Summary
Sales slid 1% to $38.9 mil. for the quarter ended Sept. 30, 2006, while net income dropped 17% to $3.6 mil, Parlux reports March 30. For the six months, net sales were up 9% to $79.7 mil., with a net loss of $10.5 mil. due to a charge related to the company's June 2006 stock split, Parlux says. "I am pleased, after over four months of delays, we are moving forward with our reporting responsibilities," interim CEO Neil J. Katz remarks. In March, Nasdaq gave Parlux a March 31 deadline to report its second- and third-quarter financials before being delisted from the stock market. Parlux has since filed the former, but will not file the latter by deadline; it has asked Nasdaq for an April 16 extension. The firm cannot be sure that Nasdaq will grant the request but expects to be able to provide an update on the status of its Nasdaq listing next week. "I am optimistic that we will be issuing our third quarter results in a short period of time. We expect that our reporting delinquencies will shortly be a thing of the past," Katz said...
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.